Clinical trials: Viral Respiratory Illnesses
COVID-19
Rehabilitation in Severely Ill Inpatients With COVID-19
Inpatient rehabilitation of severe-to-critical COVID-19 patients(A longitudinal, single-center retrospective cohort)
- Trial name
- NCT05104411
- Testing
- Rehabilitative intervention
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Seoul National University Bundang Hospital
COVID-19 Respiratory Infection, Respiratory Virus Infection
Preventing Respiratory Viral Illness Invisibly
Elderly people who have multiple health problems are at higher risk of illness from viral respiratory infections, such as influenza (the flu) and COVID-19.
- Conditions
- COVID-19 Respiratory Infection, Respiratory Virus Infection, Influenza -Like Illness
- Trial name
- PRiVII (NCT05084898)
- Testing
- Far-UVC light as an additional method of disinfection
- Where
- 3 sites in Canada
- Volunteers
- 550 people
- Sponsor
- Kenneth Rockwood
HIV Infections, Primary Health Care
HIV Indicator Diseases in Hospital and Primary Care
Patients are frequently evaluated by physicians for medical work-up of HIV indicator conditions in hospital and in primary care at the general practitioner.
- Conditions
- HIV Infections, Primary Health Care, Acquired Immunodeficiency Syndrome, Sexually Transmitted Diseases, Viral
- Trial name
- #AwareHIV (NCT05225493)
- Testing
- Peer to peer feedback, HIV rapid test
- Where
- Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Erasmus Medical Center
Post-Acute COVID-19 Syndrome
Care for Veterans Post-COVID-19
The evidence-based Concordant Care approach involves engaging in processes that: 1) validate the patient's experience, 2) develop a shared understanding of the condition, and 3) create a patient-centered, whole health-oriented…
- Trial name
- NCT05787379
- Testing
- Concordant Care Training, Education Packet Training
- Where
- United States
- Volunteers
- 348 people
- Sponsor
- VA Office of Research and Development
Gastrointestinal Infection, Respiratory Viral Infection
Wells and Enteric Disease Transmission Trial (WET - Trial)
Approximately 40 million people in the US are served by private wells, many of which are untreated. The investigators estimate that 1.29 million cases of gastrointestinal illness (GI) per year are attributed to consuming water…
- Trial name
- NCT04258059
- Testing
- Active household UV water treatment device, Inactive household UV water treatment device
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Temple University
Sars-CoV2, Covid-19
Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients
The established Insight(TM) mHealth Platform, a component of the Stephenson Cancer Center (SCC) mHealth Shared Resource will be used to create the "Symptom Tracker" app.
- Trial name
- NCT04397614
- Testing
- mHealth Assessments
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Oklahoma
COVID-19 (Coronavirus Disease 2019)
Levels of Physical Activity After SARS-CoV-2 Infection in Pre-illness Vaccinated and Unvaccinated Greek Adults.
Coronavirus infection has an impact on several aspects of everyday life including the levels of Physical Activity (PA). Investigators wish to (1) detect changes on PA levels in recovered SARS-CoV-2 (COVID-19) adults compared to…
- Trial name
- NCT05787431
- Where
- Greece
- Volunteers
- 2,000 people
- Sponsor
- Emmanouil D. Zacharakis
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza health-related outcomes of people with COVID-19 or influenza the effects of vaccines in people with COVID-19 or influenza.
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT06163677
- Testing
- COVID-19 Vaccine
- Sponsor
- Pfizer
Covid19, Sequelae of; Infection
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers").
- Conditions
- Covid19, Sequelae of; Infection, Cognitive Symptom
- Trial name
- NCT04809974
- Testing
- Niagen
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
COVID-19
Favipiravir Therapy in Adults With Mild COVID-19
Favipiravir is a selective and potent inhibitor of influenza viral RNA polymerase. It acts as a purine analogue, which selectively inhibits viral RNA-dependent RNA polymerase (RdRps).
- Trial name
- Avi-Mild (NCT04464408)
- Testing
- Favipiravir
- Where
- 7 sites in Saudi Arabia
- Volunteers
- 231 people
- Sponsor
- King Abdullah International Medical Research Center
COVID-19
Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia
The COVID-19 pneumonia has grown to be a global public health emergency since patients were first detected in Wuhan, China, in December 2019, which spread quickly to worldwide and presented a serious threat to public health.
- Trial name
- NCT04339660
- Testing
- UC-MSCs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Puren Hospital Affiliated to Wuhan University of Science and Technology
COVID-19
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein.
- Trial name
- BLAZE-5 (NCT04701658)
- Testing
- Bamlanivimab
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Advanced Care Planning, Shared Decision Making
Advance Care Planning: Communicating With Outpatients for Vital Informed Decision
This Pre-Post, open-cohort design, pragmatic trial with 150 clinicians and will evaluate the effectiveness of the use of telehealth Advanced Care Planning (ACP) Program by comparing ACP documentation among 13,000 patients over 65
- Conditions
- Advanced Care Planning, Shared Decision Making, Video Decision Aids, Communication Skills
- Trial name
- ACP-COVID (NCT04660422)
- Testing
- VitalTalk communication skills training, ACP Decisions Video Program, Intervention training:
- Where
- United States
- Volunteers
- 42,019 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
COVID-19
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19.
- Trial name
- BLAZE-1 (NCT04427501)
- Testing
- LY3819253, LY3832479, LY3853113
- Where
- 12 sites in United States
- Volunteers
- 3,307 people
- Sponsor
- Eli Lilly and Company
COVID-19, Elderly Patients
Outcomes and Prognostic Factors in COVID-19
The primary aim is to study the short-term outcome of elderly ICU patients (≥ 70 years) suffering from COVID-19 using a multicenter and multi-national approach.
- Conditions
- COVID-19, Elderly Patients, Critical Illness, Survival
- Trial name
- COVIP (NCT04321265)
- Where
- 7 sites in Denmark, France and 2 more
- Volunteers
- 1,500 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Covid-19, Critical Illness
Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19
The novel coronavirus (COVID-19) is affecting the way many people live their lives, including seeking medical care and maintaining good self-care to keep healthy.
- Conditions
- Covid-19, Critical Illness, Attitude of Health Personnel, Attitude to Health
- Trial name
- UC-COVID (NCT04373135)
- Testing
- Brief educational video
- Where
- United States
- Volunteers
- 1,971 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
COVID-19
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective for treatment of mild COVID-19 illness. Adults and adolescent participants will be followed for approximately 28 days.
- Trial name
- NCT05157269
- Testing
- Nitazoxanide, Vitamin Super-B Complex
- Sponsor
- Romark Laboratories L.C.
COVID-19
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19.
- Trial name
- BLAZE-4 (NCT04634409)
- Testing
- Bamlanivimab, Etesevimab, VIR-7831
- Where
- 141 sites in United States, Argentina and 1 more
- Volunteers
- 1,755 people
- Sponsor
- Eli Lilly and Company
Wheezing
Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial
Ten percent of infants are prescribed short-acting bronchodilators (i.e. salbutamol) for wheezing every year, yet evidence to support this treatment in children younger than two years old is scarce.
- Trial name
- KIWI (NCT04584034)
- Testing
- Salbutamol
- Sponsor
- UMC Utrecht
COVID-19, Critical Illness
Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients
Critically ill COVID-19 patients with acute respiratory failure, in the intensive care unit (ICU), often feature high respiratory drive, determining large inspiratory efforts resulting in high pressures and global and regional…
- Conditions
- COVID-19, Critical Illness, Hypoxemic Respiratory Failure, Neurocognitive Dysfunction
- Trial name
- NCT05363332
- Where
- 3 sites in Spain
- Volunteers
- 126 people
- Sponsor
- Corporacion Parc Tauli